Clinical Trials Browser

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT03618550 2026-04-16

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Recruiting

257 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT01822652 2026-04-06

GRAIN

Phase 1 Active not recruiting

11 enrolled

CNS

Neuroblastoma, Recurrence

NCT07501650 2026-03-30

Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer

Phase 1 Recruiting

6 enrolled

Head & Neck

Head and Neck Neoplasms, Recurrence

NCT05669846 2026-03-23

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

Phase 2 Recruiting

26 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT06868433 2026-03-04

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Phase 1 Recruiting

40 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT04268277 2026-02-27

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Phase 2 Terminated

22 enrolled 20 charts

Lymphoid

Neoplasms, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT04421560 2026-02-20

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Phase 1/2 Recruiting

37 enrolled

Neoplasms, Recurrence

NCT03445858 2026-02-18

Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

Phase EARLY_PHASE1 Completed

22 enrolled

Lymphoid

Lymphoma, Neoplasms, Recurrence

NCT06052839 2026-02-09

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

Phase 2 Recruiting

15 enrolled

Recurrence

NCT03082534 2026-01-28

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Phase 2 Completed

78 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Recurrence

NCT05084430 2026-01-22

Study of Pembrolizumab and M032 (NSC 733972)

Phase 1/2 Recruiting

28 enrolled

CNSSarcoma

Astrocytoma, Glioblastoma, Recurrence, Gliosarcoma

NCT03160079 2025-11-10

Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts

Phase 1/2 Completed

16 enrolled 14 charts

Lymphoid

Burkitt Lymphoma, Recurrence

NCT03383094 2025-10-07

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

Phase 2 Active not recruiting

126 enrolled

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT05263492 2025-10-02